Abstracts tagged "Minority Health"

Abstract Number: 2559 • ACR Convergence 2025
Increasing Clinical Trial Awareness in Sample of Underrepresented Systemic Lupus Erythematosus Patients
Leslie Ranken¹, Kyle Osborne², Robert Fairman³, Gregory Russell⁴, Sara Ohl² and Jessica Kearney-Bryan⁵, ¹Atrium Health Carolinas Medical Center Wake Forest School of Medicine Charlotte, Charlotte, NC, ²Atrium Health, Charlotte, NC, ³Wellstar Health, Marietta, GA, ⁴Wake Forest School of Medicine, Winston-Salem, NC, ⁵Atrium Health Carolinas Medical Center, Charlotte, NC
Background/Purpose: Underrepresented Systemic Lupus Erythematosus (SLE) patients are greatly underrepresented in SLE clinical trials. We aimed to increase clinical trial awareness with various interventions in…
Abstract Number: 2199 • ACR Convergence 2025
Disparities in Reproductive Health Counseling Among Hispanic Women with Autoimmune Rheumatic Diseases: Insights from a Patient-Reported Survey in an Urban Safety-Net Setting
Eaman Alhassan¹, Laura Kobashigawa², Vanessa Ramos², Jack Rodman² and Leanna Wise³, ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²University of Southern California, Los Angeles, ³LAGMC/Keck Medicine of USC, Los Angeles
Background/Purpose: Reproductive-age Hispanic women with rheumatoid arthritis, juvenile idiopathic arthritis (combined, inflammatory arthritis; IA), and systemic lupus erythematosus (SLE) often bear a higher disease burden…
Abstract Number: 2198 • ACR Convergence 2025
Sociocultural Influences on Pregnancy Planning for Individuals Diagnosed with SLE in an Urban Hispanic Population: A Qualitative Study with Considerations for a Holistic Approach
Andrew Ramirez¹, Alexa Montes de Oca¹, Martha Delgado¹, Mellissa withers¹ and Leanna Wise², ¹University of Southern California, Los Angeles, ²LAGMC/Keck Medicine of USC, Los Angeles
Background/Purpose: As systemic lupus erythematosus (SLE) often affects women of child-bearing age, understanding how this population makes reproductive health decisions is critical for well-rounded healthcare.…
Abstract Number: 2077 • ACR Convergence 2025
Statin-Associated Immune-Mediated Necrotizing Myopathy in Native Americans
Tam Dinh¹, Evelyn Inga¹, Janelle Francisco¹, Yvonne Waters¹, Krystle Tapia², Maheswari Muruganandam³, N. Suzanne Emil¹, Frank O'Sullivan¹ and Wilmer Sibbitt³, ¹University of New Mexico, Albuquerque, ²University of New Mexico Hospital, Albuquerque, NM, ³University of New Mexico, Albuquerque, NM
Background/Purpose: Immune-mediated necrotizing myopathy (IMNM) is an aggressive subtype of idiopathic inflammatory myopathy (IIM) associated anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (anti-HMGCR) antibodies. Recently there have been…
Abstract Number: 2074 • ACR Convergence 2025
Increased Mortality in Hispanic Males with Lymphopenia: A Descriptive and Statistical Analysis of Anti-Melanoma Differentiation-Associated Protein 5 (MDA-5) Antibody Positive Patients
Sergio Maldonado Chaar¹ and Kelly Corbitt², ¹University of Miami/Jackson Health, Miami, FL, ²University of Miami Miller School of Medicine, El Portal, FL
Background/Purpose: Anti-melanoma differentiation-associated protein 5 (MDA-5) antibody positivity in dermatomyositis (DM) is often associated with development of interstitial lung disease (ILD), with factors such as…
Abstract Number: 1915 • ACR Convergence 2025
Innovative Clinical Trial Recruitment Approaches in Lupus Research: LuCIN Site Perspectives on Use of Social Media and Artificial Intelligence
Brandon Jackson¹, Roberto Caricchio², Saira Sheikh³, Meenakshi Jolly⁴, Jennifer Meriwether⁵, Taylor Irons⁶, Taylor Adjei⁷, Caroline Donovan⁸, Carla Menezes⁷, Courtney Canton⁹, Aimee Williams¹⁰, Maya Merrell⁹ and Stacie Bell¹¹, ¹Lupus Therapeutics, Miami, FL, ²University of Massachusetts Chan Medical School, Worcester, MA, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Rush University, Chicago, IL, ⁵Lupus Therapeutics, Westminster, CO, ⁶Lupus Therapeutics, Houston, TX, ⁷Lupus Therapeutics, New York, NY, ⁸Lupus Therapeutics, Charlottesville, VA, ⁹Lupus Therapeutics, Charleston, SC, ¹⁰Lupus Therapeutics, Raleigh, NC, ¹¹Lupus Therapeutics, Lakewood, CO
Background/Purpose: Lupus disproportionately impacts racial and ethnic minorities, yet these groups remain underrepresented in clinical trials. Lupus Therapeutics, overseeing the Lupus Clinical Investigators Network (LuCIN),…
Abstract Number: 1232 • ACR Convergence 2025
Does Social Support Reduce Bodily Pain among African American Women with SLE?: Findings from a Randomized Controlled Trial
Jerik Leung¹, Tomika Caldwell², Paul Nietert³, Clara Dismuke⁴, Hetlena Johnson⁵, Edith Williams⁶ and Everette Keller³, ¹Emory University, Rollins School of Public Health, Atlanta, GA, ²Medical University of Souty Carolina, Charleston, ³Medical University of South Carolina, Charleston, SC, ⁴VA Palo Alto Health Care System, Menlo Park, ⁵Lupus Community Advocate/Researcher, Columbia, SC, ⁶University of Rochester Medical Center, Rochester, NY
Background/Purpose: Peer mentoring has been shown to be an effective intervention for chronic conditions with evidence to suggest that it might improve health related bodily…
Abstract Number: 1082 • ACR Convergence 2025
Lupus Patient Navigator Program for Improving Care Adherence for Minority Patients
Rashi Vora¹, Samiha Karim², Dulaney Wilson³, Jasvinder Singh⁴, Gary Gilkeson¹, Jim Oates¹ and Diane Kamen⁵, ¹Medical University of South Carolina, Charleston, SC, ²Emory University, Atlanta, GA, ³Medical University of South Carolina, Charleston, ⁴Baylor College of Medicine, Houston, TX, ⁵Medical University of South Carolina, Johns Island, SC
Background/Purpose: Minority patients with systemic lupus erythematosus (SLE) experience a higher disease burden and encounter more barriers to care than White patients, resulting in worse…
Abstract Number: 1060 • ACR Convergence 2025
Demographic Risk Factors, Social Vulnerability Index, and Mortality in Patients with Systemic Lupus Erythematosus
Christine Kim¹, Katherine Mitchell², Changyong Feng¹ and Allen Anandarajah³, ¹University of Rochester, Rochester, NY, ²University of Rochester, Rochester, ³University of Rochester Medical Center, Rochester, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with multi-organ involvement that is characterized by relapses and remissions. Ethnicity, socioeconomic status, gender, age, education…
Abstract Number: PP12 • ACR Convergence 2024
Healing Together: The Role of Black, Indigenous and People of Color (BIPOC) -Only Chronic Illness Spaces in Comprehensive Care
Sarah Shaw and JP Summers, Global Healthy Living Foundation, Upper Nyack, NY
Background/Purpose: As someone from the Black, Indigenous, and People of Color (BIPOC) community living with rheumatic conditions, I have experienced firsthand many challenges that people…
Abstract Number: 0160 • ACR Convergence 2024
Supplement Use in a Diverse Cohort of Individuals with SLE
Russell Ellyson¹, Jinoos Yazdany², S. Sam Lim³, Brad Pearce³ and Laura Plantinga⁴, ¹Alameda Health System, Highland Hospital, Oakland, CA, ²UCSF, San Francisco, CA, ³Emory University, Atlanta, GA, ⁴University of California, San Francisco, San Francisco, CA
Background/Purpose: Supplement use among individuals with SLE is not well-characterized, despite potential effects of some supplements on SLE activity or on treatments for SLE or…
Abstract Number: 0179 • ACR Convergence 2024
Bridging the Gap: Enhancing Diversity in Lupus Clinical Trials Through Investigator and Research Staff Engagement
Tessa Englund¹, Katherine Holben¹, Simone Frank², Khadeejatul-Kubraa Lawal¹, Julie Hsieh³, Christine Lee³ and Saira Sheikh¹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²North Carolina Translational and Clinical Sciences Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, ³U.S. Food and Drug Administration, Silver Spring, MD
Background/Purpose: Lupus disproportionately affects diverse racial and ethnic minority populations, yet there is a significant disparity between those affected and those enrolled in clinical trials.…
Abstract Number: 0180 • ACR Convergence 2024
Collaborative Solutions to Lupus Trial Challenges for Underrepresented Participant Recruitment & Engagement: Perspectives from the Lupus Clinical Investigators Network (LuCIN)
Brandon Jackson¹, Maria Dall'Era², Saira Sheikh³, Xueting Zhang⁴, Taylor Irons⁵, Claire Finney⁶, Taylor Adjei⁷, Jennifer Meriwether⁷, Caroline Donovan⁸, Carla Menezes⁹ and Stacie Bell¹⁰, ¹Lupus Research Alliance / Lupus Therapeutics, Miami, FL, ²UCSF, Corte Madera, CA, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Weill Cornell, New York, NY, ⁵Lupus Research Alliance / Lupus Therapeutics, Houston, ⁶Lupus Research Alliance / Lupus Therapeutics, Birmingham, AL, ⁷Lupus Research Alliance / Lupus Therapeutics, New York, NY, ⁸Lupus Research Alliance / Lupus Therapeutics, Arlington, VA, ⁹Lupus Research Alliance / Lupus Therapeutics, Brooklyn, NY, ¹⁰Lupus Therapeutics, Lakewood, CO
Background/Purpose: Racial and ethnic minority groups face higher lupus prevalence and severity and remain inadequately represented in lupus clinical trials. Lupus Therapeutics, the clinical affiliate…
Abstract Number: 0193 • ACR Convergence 2024
New York City Lupus Clinical Trials Education Program
Maya Souvignier¹, Leila Khalili¹, Wai Yan April Fu², Laura Geraldino³, Nancyanne Schmidt¹, Yevgeniya Gartshteyn⁴, Peter Izmirly⁵, Noa Schwartz⁶ and Anca Askanase¹, ¹Columbia University Medical Center, New York, NY, ²Albert Einstein College of Medicine, New York, NY, ³Division of Rheumatology, Department of Medicine, Columbia University, New York, NY, ⁴Columbia University Irving School of Medicine, New York, NY, ⁵New York University Grossman School of Medicine, New York, NY, ⁶Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY
Background/Purpose: Clinical trial (CT) participation is essential for the advancement of treatment paradigms and should be considered part of clinical care in SLE. CTs fail…
Abstract Number: 1015 • ACR Convergence 2024
Performance of a Molecular Signal Response Classifier Predicting Inadequate Response to Tumor Necrosis Factor Inhibitors in Hispanic Patients with Rheumatoid Arthritis
Viet Bui¹, Miguel Rodriguez² and Sarah Ormseth³, ¹Harbor UCLA Medical Center and The Lundquist Institute, Torrance, CA, ²Texas Arthritis Center, El Paso, TX, ³The Lundquist Institute, Torrance, CA
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are generally the first class of biologic disease modifying anti-rheumatic drugs (DMARDs) prescribed for rheumatoid arthritis (RA) patients with…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].